IONIS PHARMACEUTICALS INC (IONS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 400M 800M 1.2B Q3 '21: 660.7M Q4 '21: 810.5M Q1 '22: 840.8M Q2 '22: 848.8M Q3 '22: 875.5M Q4 '22: 587.4M Q1 '23: 576M Q2 '23: 630.6M Q3 '23: 615M Q4 '23: 787.6M Q1 '24: 776.6M Q2 '24: 813.5M Q3 '24: 803.1M Q4 '24: 705.1M Q1 '25: 717.3M Q2 '25: 944.1M Q3 '25: 967M Q4 '25: 943.7M Q1 '26: 1.1B Q2 '26: 874.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 400M 800M 1.2B Q3 '21: 648.8M Q4 '21: 799.6M Q1 '22: 828.3M Q2 '22: 834.6M Q3 '22: 862.8M Q4 '22: 573.2M Q1 '23: 564.7M Q2 '23: 621.5M Q3 '23: 605.3M Q4 '23: 778.5M Q1 '24: 766.7M Q2 '24: 801.9M Q3 '24: 792.6M Q4 '24: 693.9M Q1 '25: 706.7M Q2 '25: 933.5M Q3 '25: 955.2M Q4 '25: 927.8M Q1 '26: 1B Q2 '26: 858.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -273.5M Q4 '21: -30.2M Q1 '22: 4.3M Q2 '22: -8.3M Q3 '22: 18.4M Q4 '22: -410.2M Q1 '23: -466.8M Q2 '23: -471.5M Q3 '23: -555.6M Q4 '23: -353.7M Q1 '24: -389.1M Q2 '24: -365M Q3 '24: -370.4M Q4 '24: -475.1M Q1 '25: -472.4M Q2 '25: -266.5M Q3 '25: -278M Q4 '25: -381.7M Q1 '26: -352.2M Q2 '26: -594.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '21: -607.7M Q4 '21: -28.6M Q1 '22: -3.9M Q2 '22: -28.2M Q3 '22: 7.3M Q4 '22: -269.7M Q1 '23: -328.9M Q2 '23: -309M Q3 '23: -409.5M Q4 '23: -366.3M Q1 '24: -384.8M Q2 '24: -365.7M Q3 '24: -358.8M Q4 '24: -453.9M Q1 '25: -458M Q2 '25: -268.2M Q3 '25: -256.3M Q4 '25: -381.4M Q1 '26: -327M Q2 '26: -565.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 6M 12M 18M Q3 '21: 11.9M Q4 '21: 10.8M Q1 '22: 12.4M Q2 '22: 14.2M Q3 '22: 12.7M Q4 '22: 14.1M Q1 '23: 11.3M Q2 '23: 9.1M Q3 '23: 9.8M Q4 '23: 9.1M Q1 '24: 9.9M Q2 '24: 11.6M Q3 '24: 10.4M Q4 '24: 11.2M Q1 '25: 10.5M Q2 '25: 10.5M Q3 '25: 11.8M Q4 '25: 15.9M Q1 '26: 17.4M Q2 '26: 16M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-1.1B -700M -350M 0 350M 700M 1.1B Q3 '20: 215.8M Q4 '21: 30.8M Q1 '22: 53.8M Q2 '22: 98.4M Q3 '22: 129.5M Q4 '22: -274.4M Q1 '23: -376.7M Q2 '23: -456M Q3 '23: -540.6M Q4 '23: -307.5M Q1 '24: -323.5M Q2 '24: -346M Q3 '24: -351.9M Q4 '24: -500.9M Q1 '25: -501.8M Q2 '25: -230.6M Q3 '25: -247M Q4 '25: -268.6M Q1 '26: -910.6M Q2 '26: -496.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-1.1B -700M -350M 0 350M 700M 1.1B Q3 '20: 178M Q4 '21: 18.8M Q1 '22: 40.9M Q2 '22: 86.5M Q3 '22: 115.4M Q4 '22: -290.1M Q1 '23: -400.2M Q2 '23: -488.1M Q3 '23: -569.3M Q4 '23: -331.3M Q1 '24: -341.3M Q2 '24: -358M Q3 '24: -370.9M Q4 '24: -546.2M Q1 '25: -555.1M Q2 '25: -290M Q3 '25: -302.7M Q4 '25: -320M Q1 '26: -971.3M Q2 '26: -560.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '20: 139.7M Q4 '20: 140M Q1 '21: 140.8M Q2 '21: 141M Q3 '21: 141.1M Q4 '21: 160.3M Q1 '22: 141.6M Q2 '22: 141.8M Q3 '22: 141.9M Q1 '23: 142.7M Q2 '23: 143.1M Q3 '23: 143.3M Q1 '24: 145.5M Q2 '24: 146M Q3 '24: 148.6M Q1 '25: 158.7M Q2 '25: 182.3M Q3 '25: 159.8M Q1 '26: 164.9M Q2 '26: 165.4M Q4 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -4.33 Q4 '21: -0.38 Q1 '22: -0.20 Q2 '22: -0.37 Q3 '22: -0.12 Q4 '22: -1.90 Q1 '23: -2.31 Q2 '23: -2.17 Q3 '23: -2.87 Q4 '23: -2.56 Q1 '24: -2.67 Q2 '24: -2.52 Q3 '24: -2.44 Q4 '24: -3.04 Q1 '25: -2.99 Q2 '25: -1.84 Q3 '25: -1.69 Q4 '25: -2.44 Q1 '26: -2.07 Q2 '26: -3.46 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.